Action - REC

Rendering Error

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Dernier

5,702

Prix Achat

Prix Vente

Volume échangé

0,00 Fourchette du Jour 0,00

0,00 Plage de 52 semaines 0,00

Clôture Veille

5,702

Ouverture

Dernière Transaction

Dernière heure de transaction

Volume moyen (3 m)

Volume financier

VWAP

RECORDATI : SHAREHOLDERS APPROVE THE 2014 ACCOUNTS.

RECORDATI SHAREHOLDERS APPROVE THE 2014 ACCOUNTS. DIVIDEND € 0.50 PER SHARE (+51.5% vs 2013). Shareholders approve the 2014...

RECORDATI : BOARD APPROVES THE 2014 ACCOUNTS.

RECORDATI; BOARD APPROVES THE 2014 ACCOUNTS. REVENUES € 987.4 MILLION (+4.9%), OPERATING INCOME € 231.0 MILLION (+18.2%), NET...

RECORDATI : PRELIMINARY 2014 RESULTS: REVENUE GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT

PRELIMINARY 2014 RESULTS: REVENUE GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT, SALES +4.9%, OPERATING INCOME +18.2% AND NET INCOME...

RECORDATI REPORTS EXCELLENT RESULTS IN THE FIRST HALF 2014

RECORDATI REPORTS EXCELLENT RESULTS IN THE FIRST HALF 2014. SALES +6.3%, OPERATING INCOME +18.8% AND NET INCOME +18.1%. Consolidated...

RECORDATI : CARBAGLU(R) RECEIVES ORPHAN DRUG DESIGNATION IN THE U.S. FOR ORGANIC ACIDEMIAS

MILANO, Italy, July 3, 2014 (GLOBE NEWSWIRE) -- Recordati announces that the U.S. Food and Drug Administration (FDA) has granted approval of...

RECORDATI FINALIZES THE SECOND TRANCHE OF ITS ACQUISITION OF OPALIA PHARMA IN TUNISIA.

MILANO, Italy, May 26, 2014 (GLOBE NEWSWIRE) -- Recordati announces, following its previous releases dated 24 July 2013 and 31 October 2013, the...

RECORDATI: SALES GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT IN THE FIRST QUARTER 2014

Consolidated revenue € 260.4 million, +6.5%. EBITDA(1) € 71.4 million, +16.4% Operating income € 62.2 million...

RECORDATI: SHAREHOLDERS APPROVE THE 2013 ACCOUNTS. DIVIDEND EU 0.33 PER SHARE.

Shareholders approve the 2013 results: Consolidated revenue € 941.6 million, +13.7%, operating income € 195.4 million, +17.0...

RECORDATI: BOARD APPROVES THE 2013 ACCOUNTS.

MILANO, Italy, March 6, 2014 (GLOBE NEWSWIRE) -- RECORDATI: BOARD APPROVES THE 2013 ACCOUNTS. REVENUE € 941.6 MILLION (+13.7...

The European Organisation for Rare Diseases awards Orphan Europe for exceptional contribution to reducing the impact of rare ...

LA DEFENSE, France, Feb. 26, 2014 (GLOBE NEWSWIRE) -- EURORDIS (European Organisation for Rare Diseases) announced yesterday that Orphan Europe...

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	FU
4	0	0	0	0	0	0	0	FU
12	0	0	0	0	0	0	0	FU
26	0	0	0	0	0	0	0	FU
52	0	0	0	0	0	0	0	FU
156	0	0	0	0	0	0	0	FU
260	0	0	0	0	0	0	0	FU

REC - Frequently Asked Questions (FAQ)

What is the current share price?

The current share price of is US$ 5,702

What is the 1 year trading range for share price?

has traded in the range of US$ 0,00 to US$ 0,00 during the past year

Volume
% Gagnants
% Perdants

Symbole	Prix	Vol.
ALURAllurion Technologies Inc	US$ 3,42 (50,00%)	2,37M
JBIJanus International Group Inc	US$ 10,99 (36,18%)	6
BALYBallys Corporation	US$ 21,48 (25,83%)	24
GBTGGlobal Business Travel Group Inc	US$ 8,99 (16,15%)	15
LGF.BLions Gate Entertainment Corp	US$ 9,69 (12,94%)	12
SMHISEACOR Marine Holdings Inc	US$ 4,51 (-16,79%)	2
MTALMAC Copper Limited	US$ 9,15 (-14,88%)	205
VELVelocity Financial Inc	US$ 17,00 (-10,48%)	434
PLPlanet Labs PBC	US$ 3,80 (-10,38%)	12,53k
KWKennedy Wilson Holdings Inc	US$ 8,01 (-10,10%)	11
NIONIO Inc	US$ 4,41 (-6,37%)	3,69M
ALURAllurion Technologies Inc	US$ 3,42 (50,00%)	2,37M
NKENike Inc	US$ 67,44 (-6,15%)	751,92k
QBTSD Wave Quantum Inc	US$ 8,41 (-3,22%)	372,09k
XPEVXPeng Inc	US$ 21,07 (-4,53%)	240,07k

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Rydex Inverse 2X S&P Select Se (REC)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

REC Dernières nouvelles

RECORDATI : SHAREHOLDERS APPROVE THE 2014 ACCOUNTS.

RECORDATI : BOARD APPROVES THE 2014 ACCOUNTS.

RECORDATI : PRELIMINARY 2014 RESULTS: REVENUE GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT

RECORDATI REPORTS EXCELLENT RESULTS IN THE FIRST HALF 2014

RECORDATI : CARBAGLU(R) RECEIVES ORPHAN DRUG DESIGNATION IN THE U.S. FOR ORGANIC ACIDEMIAS

RECORDATI FINALIZES THE SECOND TRANCHE OF ITS ACQUISITION OF OPALIA PHARMA IN TUNISIA.

RECORDATI: SALES GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT IN THE FIRST QUARTER 2014

RECORDATI: SHAREHOLDERS APPROVE THE 2013 ACCOUNTS. DIVIDEND EU 0.33 PER SHARE.

RECORDATI: BOARD APPROVES THE 2013 ACCOUNTS.

The European Organisation for Rare Diseases awards Orphan Europe for exceptional contribution to reducing the impact of rare ...

REC - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	FU
4	0	0	0	0	0	0	0	FU
12	0	0	0	0	0	0	0	FU
26	0	0	0	0	0	0	0	FU
52	0	0	0	0	0	0	0	FU
156	0	0	0	0	0	0	0	FU
260	0	0	0	0	0	0	0	FU

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	FU
4	0	0	0	0	0	0	0	FU
12	0	0	0	0	0	0	0	FU
26	0	0	0	0	0	0	0	FU
52	0	0	0	0	0	0	0	FU
156	0	0	0	0	0	0	0	FU
260	0	0	0	0	0	0	0	FU

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

Rydex Inverse 2X S&P Select Se (REC) Cours

Rydex Inverse 2X S&P Select Se (REC)

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

REC Dernières nouvelles

RECORDATI : SHAREHOLDERS APPROVE THE 2014 ACCOUNTS.

RECORDATI : BOARD APPROVES THE 2014 ACCOUNTS.

RECORDATI : PRELIMINARY 2014 RESULTS: REVENUE GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT

RECORDATI REPORTS EXCELLENT RESULTS IN THE FIRST HALF 2014

RECORDATI : CARBAGLU(R) RECEIVES ORPHAN DRUG DESIGNATION IN THE U.S. FOR ORGANIC ACIDEMIAS

RECORDATI FINALIZES THE SECOND TRANCHE OF ITS ACQUISITION OF OPALIA PHARMA IN TUNISIA.

RECORDATI: SALES GROWTH AND SIGNIFICANT MARGIN IMPROVEMENT IN THE FIRST QUARTER 2014

RECORDATI: SHAREHOLDERS APPROVE THE 2013 ACCOUNTS. DIVIDEND EU 0.33 PER SHARE.

RECORDATI: BOARD APPROVES THE 2013 ACCOUNTS.

The European Organisation for Rare Diseases awards Orphan Europe for exceptional contribution to reducing the impact of rare ...

REC - Frequently Asked Questions (FAQ)

Moteurs

Forums

Dernières Valeurs Consultées

Société

Entreprise

Popular

Obtenir l'application

Supprimer les publicités

Période	Variation	Variation %	Ouver.	Haut	Bas	Moyenne Vol. Quot.	VWAP
1	0	0	0	0	0	0	0	FU
4	0	0	0	0	0	0	0	FU
12	0	0	0	0	0	0	0	FU
26	0	0	0	0	0	0	0	FU
52	0	0	0	0	0	0	0	FU
156	0	0	0	0	0	0	0	FU
260	0	0	0	0	0	0	0	FU